ORKAOruka Therapeutics, Inc.

Sector: Biotechnology | Filing: 10-Q | Filed: November 9, 2026

---

What Happened

Oruka Therapeutics, Inc. filed its 10-Q quarterly report with the SEC on November 9, 2026, disclosing financial results for Q3 FY2026. The company reported an operating loss of $87.6 million and a net loss of $21.0 million for the quarter. As a pre-revenue clinical-stage biopharmaceutical company — consistent with its reported $0 in revenues in prior periods — Oruka continues to fund its operations entirely through capital raises rather than product sales.

---

Why It Matters

For investors, the core takeaway is that Oruka remains in a heavy investment phase, burning through cash as it advances its pipeline. The wide gap between the operating loss ($87.6M) and the net loss ($21.0M) suggests meaningful non-operating income — such as interest income on cash reserves or other adjustments — that is partially offsetting operating expenditures. This is worth monitoring as it indicates the company may be managing its cash runway more effectively than the headline operating loss implies. The basic and diluted EPS of -$9.17 reported in Q2 FY2025 provides additional context for the per-share cost of this development-stage burn rate. With no revenues on record, the financial profile is entirely driven by R&D and administrative spend.

---

Analysis

The scale of the $87.6 million operating loss in a single quarter is notable, reflecting the capital intensity typical of clinical-stage antibody or biologics programs. What is striking, however, is that the net loss of $21.0 million is dramatically smaller — roughly 76% less than the operating loss — suggesting that investment income or other below-the-line items are providing a substantial financial cushion. This dynamic is common among well-capitalized biotechs that have raised large cash reserves, and it implies Oruka may have a longer operational runway than the operating cash burn alone would suggest.

ORKA shares are trading at $110.14, up 5.33% on the day, trading well above the $92.00 price target established in StockWatch's initiating coverage published on September 23, 2026. The market's reaction suggests investors may be reading the net loss figure — rather than the operating loss — as the more relevant near-term signal, or that pipeline developments not captured in this filing are driving sentiment.

Key items to watch going forward:

• The composition of the non-operating income offsetting the operating loss — particularly cash and equivalents on hand and their yield
• Pipeline milestone disclosures or clinical data readouts that could clarify the trajectory of spending
• Future quarterly operating losses relative to the Q3 FY2026 baseline of $87.6 million
• Cash runway estimates, which are not provided in the structured data but would be critical to assess in the full filing

---

Disclaimer

This report is a news and informational analysis based solely on data extracted from Oruka Therapeutics' SEC filing dated November 9, 2026, and publicly available market data. It does not constitute investment advice, an offer to buy or sell securities, or an equity research recommendation. No rating or price target is issued or implied herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making investment decisions.

Existing Coverage

StockWatch has full coverage on ORKA, published 2026-09-23. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-09. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/907654/000121390026117518/ea0304345-10q_oruka.htm